# Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

Study · id `cardio:ct-nct04927949` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04927949](<https://clinicaltrials.gov/study/NCT04927949>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04927949

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

## Technical summary

Registry record NCT04927949. Randomized; no masking; primary purpose treatment. Start 2021-06-08 (actual); primary completion 2023-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 128 participants (enrolled count; ClinicalTrials.gov record NCT04927949, source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)
- Started: 2021-06-08 (actual) (ClinicalTrials.gov record NCT04927949, source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)
- Primary completion: 2023-03-31 (actual) (ClinicalTrials.gov record NCT04927949, source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)
- Completion: 2023-03-31 (actual) (ClinicalTrials.gov record NCT04927949, source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04927949, source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04927949-2026-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
- Acronym: ERMIT
- Condition: ST-elevation Myocardial Infarction
- Intervention (Drug): cangrelor perfusion during PCI
- Intervention (Procedure): standard PCI
- Lead sponsor: University Hospital, Caen
- Lead sponsor class: OTHER
- Collaborator: Terumo Medical Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: University Hospital, Caen (`cardio:org-university-hospital-caen`)

## Provenance

Content hash: d95ebb77747205ff195c97dc01a9f14e701f2417c79594b01cf521a3aca34f4c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
